16 October 2024
IXICO plc
("IXICO" or the "Company")
Director/PDMR Shareholding
IXICO plc (AIM: IXI), the medical imaging advanced analytics company delivering insights in neuroscience, announces that it has been notified that on 15 October 2024, Robin Wolz, Chief Scientific Officer and a PDMR of the Company, purchased 44,000 ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") at an average price of 9.91* pence per Ordinary Share.
As a result, Robin Wolz is now interested in a total of 44,000 Ordinary Shares, representing 0.09% of the Company's issued share capital.
The information below, set out in accordance with the requirements of the UK Market Abuse Regulation, provides further detail.
* The tranactions took place on the Frankfurt Boerse at an average price of 0.119076 EUR and has been converted at the closing middle market spot price of 0.83 GBP:EUR.
- Ends -
For further information please contact:
| IXICO plc | +44 (0) 20 3763 7499 | |
| Bram Goorden, Chief Executive Officer Grant Nash, Chief Financial Officer |
| |
| |
| |
| Cavendish Capital Markets Limited (Nominated adviser and sole broker) | +44 (0) 20 7220 0500 | |
| Giles Balleny / Dan Hodkinson (Corporate Finance) | |
|
| Nigel Birks (Life Sciences Specialist Sales) Harriet Ward (Corporate Broking) Michael F Johnson / Tamar Cranford Smith (Sales) | |
|
About IXICO
IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.
IXICO has developed and deployed breakthrough data analytics, at scale, through its remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.
| 1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
| a)
| Name
| Robin Wolz
| |||
| 2
| Reason for the notification
| ||||
| a)
| Position/status
| Chief Scientific Officer and PDMR | |||
| b)
| Initial notification /Amendment
| Initial | |||
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
| a)
| Name
| IXICO plc | |||
| b)
| LEI
| 2138005M1F59O6HWSA97 | |||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
| a)
| Description of the financial instrument, type of instrument | Ordinary shares in IXICO plc
| |||
| | | ||||
| Identification code | ISIN: GB00BFXR4C20 | ||||
| | | ||||
| b)
| Nature of the transaction
| Acquisition of Ordinary shares | |||
| c)
| Price(s) and volume(s) | | | | |
| | | Price(s) | Volume(s) | | |
| | | 0.114542 EUR | 10,000 | | |
| | | 0.120713 EUR | 9,000 | | |
| | | 0.1203 EUR | 25,000 | | |
| | | | | | |
| d)
| Aggregated information | | |||
| | | ||||
| - Aggregated volume | 44,000 shares | ||||
| | | ||||
| - Price | 0.119076 EUR
| ||||
| | | ||||
| e)
| Date of the transaction
| 15 October 2024 | |||
| f)
| Place of the transaction
| Frankfurt (Germany) | |||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.